Key facts
- Active Substance
- Fusion protein composed of the first 2 immunoglobulin (Ig)-like domains of the human ROBO2 fused to human IgG1 Fc (PF-06730512)
- Therapeutic area
- Uro-nephrology
- Decision number
- P/0431/2022
- PIP number
- EMEA-003157-PIP01-21
- Pharmaceutical form(s)
- Powder for solution for injection
- Condition(s) / indication(s)
- Treatment of focal segmental glomerulosclerosis
- Route(s) of administration
- Intravenous use
- Contact for public enquiries
Pfizer Europe MA EEIG
E-mail: pip_enquiries@pfizer.com
Tel: +44 1304616161- Decision type
- P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s)
- Decision date